A patient on apixaban (Eliquis) 5 mg twice daily has developed a new clot; how should their anticoagulation be managed?

Switch to LMWH or Increase Apixaban Dose

For a patient on apixaban 5 mg twice daily who develops a new clot (breakthrough VTE), you should switch to low-molecular-weight heparin (LMWH) or consider increasing the LMWH dose by 20-25% if already on it, rather than continuing the same apixaban regimen. 1

Management Algorithm for Breakthrough VTE on Apixaban

Immediate Action Required

When VTE recurrence occurs despite therapeutic anticoagulation with apixaban, the 2022 International Clinical Practice Guidelines for cancer-associated thrombosis provide clear guidance that applies broadly to anticoagulation failure 1:

Three management options exist:

1. Switch from apixaban to LMWH (preferred option)
2. If already on LMWH, increase dose by 20-25%
3. If on vitamin K antagonist, switch to LMWH or direct oral anticoagulants

Why This Approach

The development of a new clot while on therapeutic apixaban represents anticoagulation failure. The 2016 CHEST guidelines note that while apixaban is effective for initial VTE treatment, breakthrough thrombosis requires a change in strategy 2. Simply continuing the same medication that failed is not recommended.

Cancer vs Non-Cancer Patients

If your patient has cancer:

• LMWH is strongly preferred over continuing any DOAC including apixaban 2, 1
• The 2022 guidelines specifically recommend LMWH over apixaban for cancer-associated thrombosis (Grade 1A) 1
• Cancer patients have higher thrombotic risk and may have drug-drug interactions with chemotherapy that affect apixaban levels

If your patient does NOT have cancer:

• Switching to LMWH remains the most evidence-based approach for breakthrough VTE 1
• Alternative: Some case reports describe dual anticoagulation (combining warfarin with apixaban), but this is experimental with very limited evidence and significantly increased bleeding risk 3

Critical Considerations Before Switching

Assess for causes of anticoagulation failure:

• Medication adherence: Apixaban requires strict twice-daily dosing; missed doses dramatically increase VTE risk
• Drug interactions: CYP3A4 inhibitors/inducers can alter apixaban levels
• Malabsorption: GI conditions may reduce apixaban absorption
• Renal function: Apixaban is 25% renally cleared; severe renal impairment affects levels 4
• Body weight extremes: Very high or low body weight may require dose adjustment

Verify appropriate initial dosing:

• Standard VTE treatment: 10 mg twice daily × 7 days, then 5 mg twice daily 5
• If patient was on 2.5 mg twice daily (extended prophylaxis dose), this is insufficient for acute VTE treatment

Practical Implementation

Transition from apixaban to LMWH:

1. Stop apixaban immediately
2. Begin LMWH at treatment dose (e.g., enoxaparin 1 mg/kg subcutaneously every 12 hours) at the time of the next scheduled apixaban dose 5
3. No bridging or overlap needed due to apixaban's short half-life (approximately 12 hours) 4

Duration of therapy:

• Minimum 3-6 months for acute VTE 2
• Consider indefinite anticoagulation given recurrence on therapeutic anticoagulation
• For cancer patients, continue LMWH as long as cancer is active 1

Common Pitfalls to Avoid

1. Do not simply increase apixaban dose: There is no evidence supporting doses higher than 5 mg twice daily for VTE treatment, and no approved higher-dose regimen exists 5

2. Do not add antiplatelet therapy: Adding aspirin or other antiplatelets increases bleeding risk without proven benefit for VTE 2

3. Do not assume non-adherence without investigation: While common, other factors (malignancy, thrombophilia, inadequate dosing) must be excluded

4. Avoid dual anticoagulation: The case report describing warfarin plus apixaban 3 represents experimental therapy with extreme bleeding risk and should only be considered after hematology consultation when all other options have failed

When to Consult Hematology

Immediate consultation indicated for:

• Recurrent VTE despite LMWH at increased doses
• Suspected antiphospholipid syndrome or other thrombophilia
• Consideration of inferior vena cava filter (only if anticoagulation absolutely contraindicated) 1
• Unusual clot locations (splanchnic, cerebral venous thrombosis)

The evidence strongly supports changing anticoagulation strategy rather than continuing a failed regimen, with LMWH being the most evidence-based alternative 1.